Zhitong Finance App News, China Biopharmaceutical (01177.HK) issued an announcement. The group subsidiary Beijing Tide Pharmaceutical Co., Ltd. (Beijing Tide) has obtained approval from the China National Drug Administration (NMPA) for marketing and marketing of the following diseases and symptoms: osteoarthritis, periodontitis, tendon and tenosynovitis, peritenosynovitis, humerus epicondylitis (tennis elbow), muscle pain, trauma pain. The product also received a 4-year NMPA data protection period, building a solid barrier to consolidate the Group's leading position in the market.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.